The Patent Finder

Terms ending in 2040

GlaxoSmithKline LLC

Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,555,040Oxepinopyrazole Derivatives as Inhibitors of P13-Kinase Activity
In force
 · High confidence
GlaxoSmithKline Intellectual Property Development LimitedIn forceHigh confidence
US 12,240,853Compounds Useful in HIV Therapy
In force
 · High confidence
GlaxoSmithKline Intellectual Property (No. 2) LimitedIn forceHigh confidence
US 11,963,962Platelet Count-Agnostic Methods of Treating Myelofibrosis
In force
 · High confidence
GlaxoSmithKline LLCIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by GlaxoSmithKline LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited